Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial

Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial

Abstract Background Oral Potentially Malignant Disorders (OPMD) have a non-negligible malignant transformation rate of up to 8%. Loss of heterozygosity (LOH) in critical chromosomal loci has proven to be the most effective marker in defining the risk of transformation and it is found in about 28% of...

Full description

Bibliographic Details
Main Authors: Cristina Gurizzan, Luigi Lorini, Alberto Paderno, Michele Tomasoni, Gabriele Zigliani, Anna Bozzola, Laura Ardighieri, Simonetta Battocchio, Eliana Bignotti, Antonella Ravaggi, Chiara Romani, Loris De Cecco, Mara Serena Serafini, Rosalba Miceli, Elena Bardellini, Alessandra Majorana, Cesare Piazza, Paolo Bossi
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Oral potentially malignant disorder
LOH
Malignant transformation
Immunotherapy
Prevention
Oral cancer
Online Access:https://doi.org/10.1186/s12885-021-08297-3

Similar Items

Similar Items